Pharmaguy's Insights Into Drug Industry News
187.2K views | +13 today
Follow
Pharmaguy's Insights Into Drug Industry News
Pharmaguy curates and provides insights into selected drug industry news and issues.
Curated by Pharma Guy
Your new post is loading...
Your new post is loading...
Rescooped by Pharma Guy from New pharma
Scoop.it!

Pharma reputation from a patient perspective is growing! See the latest results of 2015 survey.

Pharma reputation from a patient perspective is growing! See the latest results of 2015 survey. | Pharmaguy's Insights Into Drug Industry News | Scoop.it

Reports published in 2016 on the Corporate Reputation of Pharma, as viewed by over 1,000 patient groups

 

The corporate Reputation of Pharma is growing:
In 2011 there was 42.0% of patient groups stating that the corporate reputation of the Pharma industry is "excellent" or "good". Although this percentage decreased to a 34% in 2012, it has increased ever since to 44.7% in 2015!

For a quick summary about our methodology and series of reports on corporate reputation of pharma and medical devices view the powerpoint here

 

Of course, this global indicators must be seen from the differentiated perspectives of regions and diseases!

 

Reports of Pharma's Corporate Reputation over regions:

GLOBAL, EUROPE and EASTERN Europe; GERMANY, ITALY, NORDIC, LATIN AMERICA, SPAIN, UK & USA

 

Reports of Pharma's Corporate Reputation over therapeutic areas.:

Cancer; Circulatory conditions; Diabetes; HIV/Aids; Hepatitis; Neurological conditions; Mental health; Skin; Respiratory and Rare diseases.
Reports for Respiratory and Circulatory conditions are forthcoming. 


Via rob halkes
Pharma Guy's insight:

Related article: “Pharma's Rep Among Patient Groups at 4-Year High”; http://sco.lt/6eoNgf It should be noted that several of the patient organizations participating in this survey receive funding from the pharmaceutical industry. Also read, “#Pharma to Patient Advocacy Groups Questioning High Drug Prices: ‘Why Are You Doing This to Us?’”; http://sco.lt/4sOB7J and “Americans Hate the #Pharma Industry Almost as Much as They Hate U.S. Gov't!”; http://sco.lt/7K6aLB

more...
rob halkes's curator insight, October 18, 2016 5:50 AM

Great to seen how pharma's Corporate Reputation in the eyes of the patients is growing globally from 2011 to 2015, with a dip in 2012. Study the nuances for different global regions and Disease conditions!

Scooped by Pharma Guy
Scoop.it!

Just When We Need It, #Pharma Interest in Mental Health Wanes

Just When We Need It, #Pharma Interest in Mental Health Wanes | Pharmaguy's Insights Into Drug Industry News | Scoop.it

According to Harry Tracy, whose newsletter NeuroPerspective tracks developments in drug treatments for psychiatric problems as well as neurological conditions such as Alzheimer’s and Parkinson’s disease, the number of psychopharmacological drugs research programmes in larger drug firms has shrunk by 70% in the past decade.


“In general the larger companies have walked away from psychiatry,” he says. “There are a few companies who have maintained efforts in the area but 70% tells you it’s been a pretty remarkable departure. Many withdrew from neuroscience entirely.”


The US market researchers Kalorama Information note that generic competition has strengthened to the point where “earnings for the firms that make these drugs area are a shadow of the past”.


“SSRIs with major brands being Celexa, Lexapro, Zoloft, Prozac have greatly suffered over the years from generic competition,” publisher Bruce Carlson, of Kalorama, said. 


This pattern is reflected in sales projections compiled by Thomson Reuters Cortellis for Competitive Intelligence. It projects that by 2019 the worldwide sales of the antidepressant market leaders will be half that achieved in 2004.


Richard Friedman, professor of clinical psychiatry at Weill Cornell Medical College in New York, writes extensively on drug development and agrees with Tracy. He says that the “risk averse” industry “all but shut down their brain research”, meaning there are few signs of real innovation from drug makers.


Friedman says the lack of interest in finding the next potentially groundbreaking medications is in part due to the difficulty of bringing psychotropic drugs to market. Testing is notoriously problematic and there have been questions about how well they perform compared with placebos.


more...
No comment yet.
Scooped by Pharma Guy
Scoop.it!

Craig DeLarge Leaves Pharma to Pursue New Career in Digital Mental Health Outcomes

Craig DeLarge Leaves Pharma to Pursue New Career in Digital Mental Health Outcomes | Pharmaguy's Insights Into Drug Industry News | Scoop.it

Craig DeLarge, until yesterday, Global Leader, Multichannel Marketing Strategy & Innovation at Merck, announced his departure from the pharmaceutical industry on his Facebook timeline.

"Yesterday," said Craig, 'was my last day as ‪#‎Global‬ Leader, MCM ‪#‎Strategy‬ & ‪#‎Innovation‬ at ‪#‎Merck‬. It has been a good, highly developmental & productive 2 years at the '‪#‎leadership‬ school', I have fondly come to refer to Merck as. I am grateful for the leaders who brought me in, and the colleagues I co-developed and co-created with during my tenure.

"Moving on, I am furthering my practice in the areas of ‪#‎digitalhealthcare‬, ‪#‎changeleadership‬ and ‪#‎mentalhealth‬ outcomes. I will be taking time to explore how I can best contribute my leadership, ‪#‎creativity‬ and management in these areas in either freelance, ‪#‎consulting‬ or organizational leadership contexts.

"In particular, I will be focusing on a ‪#‎sabbatical‬ research project to map 'digital mental health' over the next 4 months as this brings together my expertise in digital health and my interest in mental health, related to my ‪#‎NAMI‬ Board work. I offer my best wishes to my management and colleagues I am leaving behind. I welcome the good wishes and assistance of any who know of opportunities for me to contribute in the three areas I mention above."

Craig has influenced countless people in his nearly 25 years within and outside the pharmaceutical industry. Let me tell you how he has influenced me. Read more about that here.

Pharma Guy's insight:


Now Craig can focus all his efforts on making a difference in the mental health arena through the confluence of his experience with digital health, change management, and outcomes. I wish him great success in his new career!

more...
No comment yet.
Scooped by Pharma Guy
Scoop.it!

Pharma companies accused of concealing risks of antidepressants

Pharma companies accused of concealing risks of antidepressants | Pharmaguy's Insights Into Drug Industry News | Scoop.it

Pharmaceutical companies have been accused of failing to report the high risk of suicide among youngsters who take antidepressants.


In the largest review of its kind, researchers from the Nordic Cochrane Center at the University of Copenhagen in Denmark, examined 70 European clinical trials involving more than 18,000 patients taking five of the most common antidepressants.


The results showed that the risk of suicide and aggression in children and adolescents taking selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) doubled.

The researchers found that after comparing clinical trial information to actual patient reports pharmaceutical companies had misclassified deaths and suicidal events to ‘favor their products.’ Instances of increased aggression were also not accurately reported.


Tarang Sharma, author of the study, which is published today in the BMJ, said manufacturers were not doing enough to highlight the dangers.


The full study can be seen here.

Pharma Guy's insight:

In general the larger companies have walked away from psychiatry. There are a few companies who have maintained efforts in the area. Many withdrew from neuroscience entirely. See "Just When We Need It, #Pharma Interest in Mental Health Wanes"; http://sco.lt/82K8gb 

more...
No comment yet.
Scooped by Pharma Guy
Scoop.it!

Do #Pharma Drug Ads in Medical Journals Perpetuate the Stigma of Depression?

Do #Pharma Drug Ads in Medical Journals Perpetuate the Stigma of Depression? | Pharmaguy's Insights Into Drug Industry News | Scoop.it

As specialists in healthcare, stigma is something we frequently encounter across many of the disease areas in which we work. This is most evident when we are conducting research directly with patients and particularly in the emerging markets, which is my team’s focus.  From sexually transmitted diseases to mental illness, shame may be associated with their condition and is a devastating reality for many of the patients we seek to understand. 


The US National Alliance on Mental Illness (NAMI) campaign to end discrimination against mental illness was heavily funded by a number of major pharmaceutical companies. Some commentators view such industry campaigns with cynicism, particularly in the more ambiguously defined and less clear cut therapy areas such as mental health. Making a label or diagnosis more ‘socially acceptable’ can be argued to be neither preventative nor curative but causative, i.e. done for the sole purpose of selling more people more drugs they don't need.
 
Pharmaceutical marketing materials have also been accused of perpetuating stigma. A 2010 literature review published in the Journal of Mental Health found that advertisements for psychiatric medication were more likely to include negative imagery and less likely to portray people in everyday situations.

Pharma Guy's insight:


Here's some comments from the authors of the research mentioned:


The way thapsychiatric medicatiois advertisein professional journals continues toperpetuate certain images and ideas regarding mental ill health. It is clearly separated fromany other health problem: advertisements for psychiatric medication are likely to containimages of people portrayed in abnormal situations in a negative way, and to include less textthan advertisements for non-psychiatric medication. The text that is used is more likely tofocus on narrative description of ‘case studies’ of people suffering from a particular mental health problerather than on anspecifimedically-relateinformatioabouthemedication itself: these individuals are almost always portrayed before any treatment, incontrast to individuals in advertisements for non-psychiatric medication, who are portrayedas living happily and actively after successful treatment.


In addition to any effects on the professionals who encounter these advertisements, thereis also thhighly importanissuof thoveralmessagthat differencebetweenadvertisements for psychiatric and non-psychiatric medication sends to client and patientpopulations, and indeed to the wider general public. To maintain a distinction betweenmental health problems and other health problems, and in particular to portray mental illhealth more in terms of chaos, deviance, fear and Otherness risks perpetuating stigma thatprofessionals, and service users, may strive so hard to dismantle in other areas.


Read the research here: http://bit.ly/1MKd8En



more...
No comment yet.